{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:07:23Z","timestamp":1789592843329,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.ejpb.2012.04.019","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T18:27:41Z","timestamp":1335896861000},"page":"600-608","source":"Crossref","is-referenced-by-count":71,"title":["Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice"],"prefix":"10.1016","volume":"81","author":[{"given":"Nicole A.","family":"Beinborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh D.C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2012.04.019_b0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1586\/14787210.3.4.613","article-title":"Invasive pulmonary aspergillosis","volume":"3","author":"Doffman","year":"2005","journal-title":"Expert Review of Anti-Infective Therapy"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2012.04.019_b0010","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0924-8579(08)70009-8","article-title":"Epidemiology of invasive fungal infection","volume":"32","author":"Caston-Osorio","year":"2008","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2012.04.019_b0015","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0924-8579(08)70016-5","article-title":"Update on the epidemiology and diagnosis of invasive fungal infection","volume":"32","author":"Cuenca-Estrella","year":"2008","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.ejpb.2012.04.019_b0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.ejpb.2012.04.019_b0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.ejpb.2012.04.019_b0030","unstructured":"FDA, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000."},{"key":"10.1016\/j.ejpb.2012.04.019_b0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10570-006-9076-x","article-title":"Solubility and dissolution studies of antifungal drug: hydroxybutenyl-b-cyclodextrin complexes","volume":"14","author":"Buchanan","year":"2007","journal-title":"Cellulose"},{"key":"10.1016\/j.ejpb.2012.04.019_b0040","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.00885-08","article-title":"Concentrations of voriconazole in healthy and inflamed lung in rats","volume":"53","author":"Joukhadar","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.ejpb.2012.04.019_b0045","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/AAC.00949-10","article-title":"Human tissue distribution of voriconazole","volume":"55","author":"Weiler","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2012.04.019_b0050","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0924-8579(08)70012-8","article-title":"Risk factors for invasive fungal infections in haematopoietic stem cell transplantation","volume":"32","author":"Camps","year":"2008","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.ejpb.2012.04.019_b0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ejpb.2012.04.019_b0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejpb.2012.04.019_b0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ejpb.2012.04.019_b0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.ejpb.2012.04.019_b0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ejpb.2012.04.019_b0080","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2012.04.019_b0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","article-title":"Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution","volume":"72","author":"Tolman","year":"2009","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0090","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.01657-08","article-title":"Inhaled voriconazole for prevention of invasive pulmonary aspergillosis","volume":"53","author":"Tolman","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.ejpb.2012.04.019_b0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","article-title":"Particle engineering for pulmonary drug delivery","volume":"24","author":"Chow","year":"2007","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.ejpb.2012.04.019_b0100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0169-409X(03)00078-4","article-title":"Novel alternative methods for the delivery of drugs for the treatment of asthma","volume":"55","author":"Chan","year":"2003","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ejpb.2012.04.019_b0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejpb.2008.09.018","article-title":"Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions","volume":"71","author":"Bhavna","year":"2009","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0110","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2012.04.019_b0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles \u2013 a current review","volume":"356","author":"Yang","year":"2008","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.05.003","article-title":"High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers","volume":"361","author":"Yang","year":"2008","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1773-2247(09)50016-0","article-title":"Use of thin film freezing to enable drug delivery: a review","volume":"19","author":"Overhoff","year":"2009","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.ejpb.2012.04.019_b0130","unstructured":"K.P. Johnston, J. Engstrom, J. Tam, A. Watts, Compositions and Methods of Making Brittle-matrix Particles through Blister Pack Freezing, US Patent Application 2010\/0221343, 2010."},{"key":"10.1016\/j.ejpb.2012.04.019_b0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejpb.2006.07.012","article-title":"Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs","volume":"65","author":"Overhoff","year":"2007","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0140","unstructured":"United States Pharmacopeia, General Chapter 601: Aerosols, Nasal sprays, Metered-dose inhalers, and Dry powder inhalers, in: USP 32-NF 27, Rockville, MD, USA, 2010."},{"key":"10.1016\/j.ejpb.2012.04.019_b0145","series-title":"To the Lungs-14","first-page":"75","article-title":"Practices of coating collection surfaces of cascade impactors: A survey of members of the European Pharmaceutical Aerosol Group (EPAG)","author":"Mitchell","year":"2003"},{"key":"10.1016\/j.ejpb.2012.04.019_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14227\/DT170210P6","article-title":"Optimization of an in vitro dissolution test method for inhalation formulations","volume":"17","author":"Son","year":"2010","journal-title":"Dissolution Technologies"},{"key":"10.1016\/j.ejpb.2012.04.019_b0155","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharmaceutical Technology"},{"key":"10.1016\/j.ejpb.2012.04.019_b0160","unstructured":"FDA, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997."},{"key":"10.1016\/j.ejpb.2012.04.019_b0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tube.2009.07.001","article-title":"Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies","volume":"89","author":"Morello","year":"2009","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejpb.2012.04.019_b0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ejpb.2012.04.019_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.00957-06","article-title":"Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods","volume":"51","author":"Pascual","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.ejpb.2012.04.019_b0180","article-title":"Effect of process variables on morphology of voriconazole formulations produced by thin film freezing","volume":"12","author":"Beinborn","year":"2010","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.ejpb.2012.04.019_b0185","unstructured":"SYMBICORT\u00ae prescribing information. <http:\/\/www1.astrazeneca-us.com\/pi\/symbicort\/pdf> (cited 07.08.11)."},{"key":"10.1016\/j.ejpb.2012.04.019_b0190","unstructured":"FDA-CDER. <http:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm> (cited 07.08.11)."},{"key":"10.1016\/j.ejpb.2012.04.019_b0195","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejpb.2008.07.004","article-title":"Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats","volume":"70","author":"Liu","year":"2008","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0200","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"Latge","year":"1999","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.ejpb.2012.04.019_b0205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11095-005-9144-1","article-title":"Determination of the surface free energy of crystalline and amorphous lactose by atomic force microscopy adhesion measurement","volume":"23","author":"Zhang","year":"2006","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.ejpb.2012.04.019_b0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","volume":"17","author":"Hancock","year":"2000","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.ejpb.2012.04.019_b0215","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1002\/jps.21367","article-title":"Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution","volume":"97","author":"Tam","year":"2008","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2012.04.019_b0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2012.04.019_b0225","series-title":"Inhalation Aerosols: Physical and Biological Basis for Therapy","first-page":"83","article-title":"Physiology and pharmacology of the airways","author":"Altiere","year":"2007"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T04:08:21Z","timestamp":1561694901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641112001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0939641112001348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2012.04.019","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}